Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host

Little, Richard F.; Yarchoan, Robert

« Previous Next »Seminars in Hematology
Volume 40, Issue 2 , Pages 163-171, April 2003

Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host☆☆☆

HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda MD.

Address correspondence to Richard F. Little, MD, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bldg 10, Room 10S255, MSC 1868, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892.

Abstract

Neoplastic disease is a frequent complication in patients with acquired immunodeficiency disease (AIDS) and other immunodeficiencies. Many such neoplasms are caused by either Epstein-Barr virus (EBV) or Kaposi's sarcoma-associated herpes virus (KSHV). The treatment of such patients can be challenging. At the same time, the viral origin of these tumors offers targets to develop pathogenesis-based therapies. Standard therapies for these diseases involve such approaches as treating the underlying immunodeficiency, cytotoxic chemotherapy, and immunologic antitumor therapy. Novel therapy approaches include specific immune therapy and anti-angiogenesis approaches, now under development. Semin Hematol 40:163-171. This is a US government work. There are no restrictions on its use.